drugset / Trial / NCT01481974

Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplantation

NCT01481974

Phase 1 Completed 35 enrolled Abhinav Humar, MD
NaSingle-groupOpen-labelTreatment

Summary

The overall purpose of this study is to evaluate the safety, pharmacokinetics and preliminary efficacy of a five-days post-operative course of Treprostinil in liver transplant patients. The hypothesis of this study is that Treprostinil can be safely administered post-operatively in liver transplant patients. Once safety is documented future studies will address its ability to ameliorate or prevent reperfusion mediated dysfunction of the liver graft and thereby reduce morbidity, leading to shorter hospital stays as compared to historical controls.

Timeline

Start
2012-12
Primary completion
2019-05-18
Completion
2019-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified

Indications